

Minutes of the Supplier Advisory Panel Meeting Wednesday 8 April 2026

This meeting was held online from 2.00 to 3.00pm.

Present:

Members:

Liz Naylor (AstraZeneca)
Michaela Lion (AbbVie)
Kate King (Medtronic)
Francis Lawes (Pfizer)
Angela Pantano (Roche)
Lindsay Ancelet (GSK)K
Kylie Earle (Sanofi)

Reset Programme staff:

Jannel Fisher (Reset Programme Manager)
Becky Littlewood (Programme Coordinator)
Hendrik Furstenu (Programme Advisor)

Pharmac staff attendees:

Ben Campbell-Macdonald (Manager, Pharmaceutical Assessment)
Caro De Luca (Manager Expert Advisory)
Ginette Spence (Senior Project Manager, Medical Devices)
Lauren Romanos (Senior Exceptions Advisor)
Susan Melvin (Senior Policy Advisor)
Tyson Edwards (Senior Therapeutic Group Manager / Team Leader)

Apologies:

Matt Needham (Roche)

Karakia and welcome

The meeting was opened by the chair.

Minutes of previous meeting

Minutes of the previous meeting minutes were approved.

- Moved by: Liz Naylor
- Seconded by: Francis Lawes

Action items

- Action items were noted.

Interest register

- No new interest declarations.

Exceptional Circumstances Framework

Pharmac provided an overview of its consultation on the Exceptional Circumstances Framework. The framework describes how Pharmac considers funding decisions for exceptional cases that sit outside the standard Pharmaceutical Schedule process and guides its decision-making in these situations.

The review will include a two-stage consultation process. The first consultation stage will be open until 7 June 2026, with the second stage planned for September 2026, and a final decision expected by March 2027. Information about the review is available on the Pharmac website and feedback can be submitted via the Citizen Space platform. Pharmac is also planning meetings with stakeholder groups to discuss and help inform the review.

Members asked questions about the current process, the purpose of the review, and the future vision for exceptional circumstances in relation to medical devices.

Action:

- *Members to contact Pharmac to arrange a meeting to discuss feedback if required.*

Application backlog pilot

Pharmac provided an update on a pilot project to reduce the backlog of historic applications, noting that it is progressing well. The discussion focused on whether the approach is appropriate, transparent, and free from unintended consequences from a supplier perspective.

Pharmac confirmed that there has been no change to the existing supplier submission process. Potential improvements to the application process are being considered as part of future improvement work.

Members expressed support for the pilot approach and its objectives, including reducing the backlog of historic applications and creating capacity to undertake assessments of innovative medicines.

General business

- Michaela Lion (AbbVie) agreed to act as the next Chair.

Close of meeting at 3.00pm

Next meeting: 13 May 2026